SHARE

Pfizer Inc (NYSE:PFE), one of the industry leaders in the provision of biopharmaceutical products. The two are in a joint effort to try and develop a novel predictive toxicology assay and that will be made possible through using the InSphero 3D InSight™ Human Liver Microtissues.

According to some trusted sources, the novel mechanistic in vitro assay is expected to target leveraging the enhanced sensitivity as well as longevity of InSphero 3D liver models, which as a matter of fact might facilitate the multiplexing of several endpoints to assist predict as well as detect mechanisms of drug toxicity. This in its own right sounds good for patients around the globe and it is thanks to the numerous technological advancements being witnessed from across the board.

Dr. Jan Lichtenberg, says, who is currently the sitting CEO and co-founder of InSphero has moved ahead to assert , “Our 3D liver models enable researchers to better predict potential toxicity and side-effects using more biologically relevant cell based assays.

These models may also help reduce dependency on animal models, which add significant cost, delay time to market, and often fail to precisely reflect how humans will respond to a drug. We already have a long-standing relationship with Pfizer and this new agreement will facilitate the development of assays with potentially even greater utility and predictive power for Pfizer’s early drug development.”

According to one of the provider’s top executives, the company belives it is redirecting its resources to the right channels and that a lot of people will get to benefit as a result. Hope lingers and the company is on track towards the achievement of the highest levels of business success.

The official that will be entrusted with spearheading the project for InSphero, Dr. Simon Messner has been quite vocal and lately he moved ahead to say, “The longevity and organotypic nature of 3D InSight™ Human Liver Micro tissues highly correlates to that of native liver, showcasing appropriate cellular organization, cytochrome P450 enzyme responsiveness, and metabolic functionality. Using this 3D model could result in improved accuracy and precision by which particular DILI mechanisms are predicted in vitro.”

The company hopes to make significant progress, but we just have to leave it to time to find out.

LEAVE A REPLY